Overview
| Generic Names: | FAMP; Fludarabine 5'-monophosphate; Fludarabine monophosphate; Fludarabine phosphate |
|---|---|
| Trade Names: | Fludara; Fludura |
| PharmGKB Accession Id: | PA449655 |
Description
Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. Wikipedia (source: Drug Bank)
Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen (source: Drug Bank)
ATC Therapeutic Category
- L01BB:Purine analogues
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. (source: Drug Bank)
Pharmacology
Fludarabine is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia. It acts at DNA polymerase alpha, ribonucleotide reductase and DNA primase, results in the inhibition of DNA synthesis, and destroys the cancer cells. (source: Drug Bank)
Food Interactions
Food slightly increases product bioavailability.
Take without regard to meals.
(source:
Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Protein Binding
19-29% (source: Drug Bank)
Absorption
Bioavailability is 55% following oral administration. (source: Drug Bank)
Isomeric SMILES Code:
c1nc2c(nc(nc2n1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
SLC28A2 |
|
Publications |
|
|
SLC28A3 |
|
Publications |
|
|
SLC29A1 |
|
Publications |
|
|
SLC29A2 |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| BCL2 |
|
(source: Drug Bank) |
| ADA |
|
(source: Drug Bank) |
| POLA1 |
|
(source: Drug Bank) |
| RRM1 |
|
(source: Drug Bank) |
| STAT1 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| dipyridamole |
|
Dipyridamole decreases the effect of fludarabine (source: Drug Bank) |
| pentostatin |
|
Unacceptable pulmonary toxicity (source: Drug Bank) |
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Leukemia, Lymphocytic, Chronic, B-Cell |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Curated Phenotype Datasets
These datasets are sorted alphabetically by title.
Downloads
You must sign in before you can download data.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.